• Immunome, Inc. recently dosed the first patient in a Phase 1, first-in-human trial of IM-1617, a potential first-in-class antibody-drug conjugate for advanced solid tumors, incorporating its proprietary TOP1 inhibitor payload HC74.
• The trial advances Immunome’s antibody-drug conjugate platform by targeting an undisclosed receptor tyrosine kinase linked to tumor survival and immune cell exclusion, with additional IND filings for IM-1340 and IM-1335 planned for mid- and late 2026.
• We will now assess how the launch of IM-1617’s first-in-human trial shapes Immunome’s investment narrative and development priorities.

Find 44 companies with promising cash flow potential yet trading below their fair value.

What Is Immunome's Investment Narrative?

For Immunome, you have to believe in the company’s ability to turn a broad oncology pipeline into something commercially meaningful, despite very limited revenue and ongoing heavy losses. The first-in-human dosing of IM-1617 adds another genuine clinical catalyst alongside the pending FDA decision on varegacestat and planned INDs for IM-1340 and IM-1335, sharpening the story around its antibody-drug conjugate platform rather than transforming it overnight. In the near term, IM-1617’s main effect is to increase operational focus on early safety data and execution across multiple trials at once, rather than to change the fundamental risk profile. The biggest questions still sit around funding needs, dilution, and whether any program can progress far enough to support a shift away from persistent net losses.

However, investors should not ignore how financing and dilution could shape future returns. Immunome's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Explore 2 other fair value estimates on Immunome - why the stock might be worth just $35.77!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunome's overall financial health at a glance.

No Opportunity In Immunome?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.